Study drug for advanced GIST tumors with specific gene mutations
Part of Cancer, Digestive system clinical trials.
This early-phase study tests inlexisertib (a targeted cancer drug) combined with other anticancer treatments in adults with advanced GIST. It is mainly looking for safety and the best way to dose, and it may help tumors that have certain KIT or PDGFRA gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have advanced GIST (gastrointestinal stromal tumor) confirmed on testing, with specific gene mutations (KIT or PDGFRA, and for one part also KIT exon 11)
- Your cancer should have gotten worse after the standard medicine(s) for GIST (or you could not tolerate them, as described) and you must not have had ripretinib before (for the parts that enroll)
- Have at least one measurable tumor spot on scans, plus enough health/lab test results to safely take study treatment
- Be able to get a fresh tumor biopsy if your care team can safely do it
- Be well enough to do daily activities (ECOG performance status 0–1) and have an estimated life expectancy of more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KQB198 combined with imatinib for people with advanced or metastatic gastrointestinal stromal tumor (GIST) that has a specific KIT or PDGFRA mutation. The goal is to see if this combination works better than imatinib alone as a first treatment.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This trial tests whether adding radiation therapy to the drug ripretinib can help people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery and have stopped responding to other treatments. It aims to see if this combination is safe and effective.
This study tests a combination of two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—for people with advanced GIST whose tumors have a specific KIT gene mutation (exon 17) and have stopped responding to standard treatments.
Hear when a new GIST trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.